What Patients Need to Know About Tecvayli


In this blog, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie provides details on Tecvayli™ (teclistamab-cqyv)— a bispecific antibody approved by the FDA for the treatment of relapsed or refractory multiple myeloma (RRMM). Dr. Durie looks forward to the ever-evolving field of immune therapies. He advise patients on how to stay well-informed about these rapid treatment innovations. https://www.myeloma.org/blog/what-patients-need-to-know-about-tecvayli

Related Videos
Dr. Mikhael in an interview with CURE